Jim Cramer on Eli Lilly and Company (LLY): ‘There’s Been Some Mistakes’
We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...
GlobalData on MSN12h
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m
Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
Eli Lilly & Co: Strong Growth Prospects and Strategic Positioning Justify Buy Rating
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Lilly Stock Drops 7% as 2024 Revenue Projection Falls Short of Guidance
Lilly gave hopeful income projections for 2025 ranging from $58 billion to $61 billion, therefore showing a midpoint rise of ...
Eli Lilly & Co (LLY) Gets a Buy from Jefferies
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
GlobalData on MSN2d
Eli Lilly targets Scorpion Therapeutics to expand reach in oncology
After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...
Remedium Lifecare Lands ₹8,500 Crore Deal From Eli Lilly &Company: A New Era in Pharma Begin
High Return on Equity: With a three-year average ROE of 101% and an ROE of 123% in the last year, the company has ...
Eli Lilly and Company: Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...